Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReMEdi trial of PHOE-01 in ME/CFS
ISRCTN74088209Phase 2Completed
- Sponsor
- Tiefenbacher
- Start
- Feb 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of pyridostigmine in myalgic encephalomyelitis (ME) (2 arms), sponsored by Tiefenbacher. Started Feb 2025; status: completed.
02
Drugs
pyridostigmine
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on ISRCTN74088209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN74088209.